Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.

Comparisons between regions over follow-up After differences in demographics and baseline clinical variables, including blood pressure and medication use, were allowed for, there were highly significant ( P ≤ 0.001) differences in event rates during follow-up for all outcomes when all three regions were compared against each other ( Table 3 ).

also in 132,142 other papers

Adjustment for age, sex, and duration of diabetes made little difference, except that insulin use then became marginally nonsignificant ( P = 0.06) ( Table 2 ).

also in 448 other papers